Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Merger Agreement with Palvella Therapeutics, Inc. (Details Textual)

v3.24.3
Note 11 - Merger Agreement with Palvella Therapeutics, Inc. (Details Textual)
Jul. 23, 2024
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
Pre-funded Warrants [Member]    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares 2,592,585  
Class of Warrant or Right, Exercise Price, Subtracted Amount From Purchase Price, Per Share $ 0.001  
Class of Warrant or Right, Maximum Beneficial Percentage Ownership If Exercised 4.99%  
Class of Warrant or Right, Maximum Percentage of Shares Outstanding if Exercised 9.99%  
Class of Warrant or Right, Maximum Percentage Beneficial Ownership With Notice 19.99%  
Securities Purchase Agreement [Member]    
Stock Issued During Period, Shares, New Issues (in shares) | shares 3,154,241  
Shares Issued, Price Per Share (in dollars per share) | $ / shares $ 13.7299  
Shares Issued, Price Per Share, Multiplier 0.315478  
Proceeds from Issuance or Sale of Equity $ 78,900,000  
Palvella [Member]    
Contingency, Termination Fee Payable   $ 1,000,000
Contingency, Termination Fee, Receivable   $ 2,000,000
Pieris Pharmaceutical Stockholders [Member]    
Ownership Percentage   18.00%
Pavella Stockholders [Member]    
Ownership Percentage   82.00%
Palvella Merger [Member]    
Merger, Cash Threshold 11,000,000  
Palvella Merger [Member] | Palvella [Member]    
Company Valuation 95,000,000  
Palvella Merger [Member] | Pieris Pharmaceutical Stockholders [Member]    
Company Valuation $ 21,000,000